Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
MNICF Quote, Financials, Valuation and Earnings
Last price:
$12.82
Seasonality move
:
0%
Day range:
$12.82 - $12.82
52-week range:
$12.82 - $12.82
Dividend yield:
2.06%
P/E ratio:
38.36x
P/S ratio:
6.25x
P/B ratio:
3.60x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$1.3B
Revenue:
$201.4M
EPS (TTM):
$0.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MNICF
Mani, Inc.
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes, Inc.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MNICF
Mani, Inc.
|
$12.82 | -- | $1.3B | 38.36x | $0.11 | 2.06% | 6.25x |
|
AMGXF
AnGes, Inc.
|
$0.36 | -- | $142.5M | -- | $0.00 | 0% | 21.89x |
|
HLOSF
Healios KK
|
$2.20 | -- | $297M | -- | $0.00 | 0% | 343.65x |
|
PPTDF
PeptiDream Inc.
|
$8.18 | -- | $1.1B | 13.79x | $0.00 | 0% | 8.56x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.28 | -- | $477.8M | -- | $0.00 | 0% | 2.40x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MNICF
Mani, Inc.
|
0.12% | -0.012 | 0.03% | 6.05x |
|
AMGXF
AnGes, Inc.
|
1.74% | 0.000 | 0.25% | 0.89x |
|
HLOSF
Healios KK
|
34.82% | 2.114 | 7.46% | 1.83x |
|
PPTDF
PeptiDream Inc.
|
27.41% | 1.316 | 7.7% | 1.47x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
48.47% | 0.726 | 73.82% | 1.51x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MNICF
Mani, Inc.
|
$34.1M | $14.9M | 9.22% | 9.23% | 28.81% | -- |
|
AMGXF
AnGes, Inc.
|
$399.5K | -$10.4M | -153.93% | -162.7% | -703% | -- |
|
HLOSF
Healios KK
|
-$798.3K | -$6.6M | -44.36% | -88.96% | -4043.07% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$17.4M | -$6M | -5.2% | -7.06% | -16.33% | -$2.8M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$37.1M | -$8.9M | -9.66% | -19.06% | -17.59% | -$1M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
Mani, Inc. vs. Competitors
-
Which has Higher Returns MNICF or AMGXF?
AnGes, Inc. has a net margin of 24.22% compared to Mani, Inc.'s net margin of -190.55%. Mani, Inc.'s return on equity of 9.23% beat AnGes, Inc.'s return on equity of -162.7%.
Company Gross Margin Earnings Per Share Invested Capital MNICFMani, Inc.65.9% $0.13 $350.9M AMGXFAnGes, Inc.27% -$0.01 $20M -
What do Analysts Say About MNICF or AMGXF?
Mani, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mani, Inc. has higher upside potential than AnGes, Inc., analysts believe Mani, Inc. is more attractive than AnGes, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNICFMani, Inc.0 0 0 AMGXFAnGes, Inc.0 0 0 -
Is MNICF or AMGXF More Risky?
Mani, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AnGes, Inc. has a beta of 0.039, suggesting its less volatile than the S&P 500 by 96.075%.
-
Which is a Better Dividend Stock MNICF or AMGXF?
Mani, Inc. has a quarterly dividend of $0.11 per share corresponding to a yield of 2.06%. AnGes, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mani, Inc. pays 82.75% of its earnings as a dividend. AnGes, Inc. pays out -- of its earnings as a dividend. Mani, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MNICF or AMGXF?
Mani, Inc. quarterly revenues are $51.8M, which are larger than AnGes, Inc. quarterly revenues of $1.5M. Mani, Inc.'s net income of $12.5M is higher than AnGes, Inc.'s net income of -$2.8M. Notably, Mani, Inc.'s price-to-earnings ratio is 38.36x while AnGes, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mani, Inc. is 6.25x versus 21.89x for AnGes, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNICFMani, Inc.6.25x 38.36x $51.8M $12.5M AMGXFAnGes, Inc.21.89x -- $1.5M -$2.8M
-
Which has Higher Returns MNICF or HLOSF?
Healios KK has a net margin of 24.22% compared to Mani, Inc.'s net margin of -9751.87%. Mani, Inc.'s return on equity of 9.23% beat Healios KK's return on equity of -88.96%.
Company Gross Margin Earnings Per Share Invested Capital MNICFMani, Inc.65.9% $0.13 $350.9M HLOSFHealios KK-491.87% $0.11 $47.9M -
What do Analysts Say About MNICF or HLOSF?
Mani, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Mani, Inc. has higher upside potential than Healios KK, analysts believe Mani, Inc. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings MNICFMani, Inc.0 0 0 HLOSFHealios KK0 0 0 -
Is MNICF or HLOSF More Risky?
Mani, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Healios KK has a beta of 0.237, suggesting its less volatile than the S&P 500 by 76.316%.
-
Which is a Better Dividend Stock MNICF or HLOSF?
Mani, Inc. has a quarterly dividend of $0.11 per share corresponding to a yield of 2.06%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mani, Inc. pays 82.75% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Mani, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MNICF or HLOSF?
Mani, Inc. quarterly revenues are $51.8M, which are larger than Healios KK quarterly revenues of $162.3K. Mani, Inc.'s net income of $12.5M is higher than Healios KK's net income of $12.4M. Notably, Mani, Inc.'s price-to-earnings ratio is 38.36x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mani, Inc. is 6.25x versus 343.65x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNICFMani, Inc.6.25x 38.36x $51.8M $12.5M HLOSFHealios KK343.65x -- $162.3K $12.4M
-
Which has Higher Returns MNICF or PPTDF?
PeptiDream Inc. has a net margin of 24.22% compared to Mani, Inc.'s net margin of -9.39%. Mani, Inc.'s return on equity of 9.23% beat PeptiDream Inc.'s return on equity of -7.06%.
Company Gross Margin Earnings Per Share Invested Capital MNICFMani, Inc.65.9% $0.13 $350.9M PPTDFPeptiDream Inc.47.44% -$0.03 $452.8M -
What do Analysts Say About MNICF or PPTDF?
Mani, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mani, Inc. has higher upside potential than PeptiDream Inc., analysts believe Mani, Inc. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNICFMani, Inc.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is MNICF or PPTDF More Risky?
Mani, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.672, suggesting its less volatile than the S&P 500 by 32.786%.
-
Which is a Better Dividend Stock MNICF or PPTDF?
Mani, Inc. has a quarterly dividend of $0.11 per share corresponding to a yield of 2.06%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mani, Inc. pays 82.75% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Mani, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MNICF or PPTDF?
Mani, Inc. quarterly revenues are $51.8M, which are larger than PeptiDream Inc. quarterly revenues of $36.8M. Mani, Inc.'s net income of $12.5M is higher than PeptiDream Inc.'s net income of -$3.5M. Notably, Mani, Inc.'s price-to-earnings ratio is 38.36x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mani, Inc. is 6.25x versus 8.56x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNICFMani, Inc.6.25x 38.36x $51.8M $12.5M PPTDFPeptiDream Inc.8.56x 13.79x $36.8M -$3.5M
-
Which has Higher Returns MNICF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 24.22% compared to Mani, Inc.'s net margin of -99.41%. Mani, Inc.'s return on equity of 9.23% beat Nxera Pharma Co., Ltd.'s return on equity of -19.06%.
Company Gross Margin Earnings Per Share Invested Capital MNICFMani, Inc.65.9% $0.13 $350.9M SOLTFNxera Pharma Co., Ltd.73.58% -$0.55 $755.2M -
What do Analysts Say About MNICF or SOLTF?
Mani, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mani, Inc. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Mani, Inc. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MNICFMani, Inc.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is MNICF or SOLTF More Risky?
Mani, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.021, suggesting its less volatile than the S&P 500 by 97.926%.
-
Which is a Better Dividend Stock MNICF or SOLTF?
Mani, Inc. has a quarterly dividend of $0.11 per share corresponding to a yield of 2.06%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mani, Inc. pays 82.75% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Mani, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MNICF or SOLTF?
Mani, Inc. quarterly revenues are $51.8M, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $50.4M. Mani, Inc.'s net income of $12.5M is higher than Nxera Pharma Co., Ltd.'s net income of -$50.1M. Notably, Mani, Inc.'s price-to-earnings ratio is 38.36x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mani, Inc. is 6.25x versus 2.40x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNICFMani, Inc.6.25x 38.36x $51.8M $12.5M SOLTFNxera Pharma Co., Ltd.2.40x -- $50.4M -$50.1M
-
Which has Higher Returns MNICF or STMM?
Stemcell Holdings, Inc. has a net margin of 24.22% compared to Mani, Inc.'s net margin of --. Mani, Inc.'s return on equity of 9.23% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MNICFMani, Inc.65.9% $0.13 $350.9M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About MNICF or STMM?
Mani, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mani, Inc. has higher upside potential than Stemcell Holdings, Inc., analysts believe Mani, Inc. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MNICFMani, Inc.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is MNICF or STMM More Risky?
Mani, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MNICF or STMM?
Mani, Inc. has a quarterly dividend of $0.11 per share corresponding to a yield of 2.06%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mani, Inc. pays 82.75% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Mani, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MNICF or STMM?
Mani, Inc. quarterly revenues are $51.8M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Mani, Inc.'s net income of $12.5M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Mani, Inc.'s price-to-earnings ratio is 38.36x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mani, Inc. is 6.25x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MNICFMani, Inc.6.25x 38.36x $51.8M $12.5M STMMStemcell Holdings, Inc.0.17x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
